All three direct FXa inhibitors and the direct thrombin inhibitor dabigatran have been shown to have a superior net clinical benefit compared with vitamin K antagonists for the treatment of venous thromboembolic events and for the prevention of stroke in patients with atrial fibrillation. This evidence concerns the gene F10 and Stroke.